Geron Corp (GERN) Reports First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis
Go back to Geron Corp (GERN) Reports First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis| Geron Corp (NASDAQ: GERN) | Delayed: 3.50 -0.23 (6.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.73 | 52 Week High | $5.30 | |||
| Open | $3.72 | 52 Week Low | $1.81 | |||
| Day High | $3.82 | P/E | N/A | |||
| Day Low | $3.49 | EPS | $-0.35 | |||
| Volume | 10,388,433 | |||||
